Evidence map›Paper›PMID 41711426›Full record

ArticlePediatric pulmonology2026

Linear Growth in Children With Cystic Fibrosis in the Netherlands Born Between 1997-2004; Results of a Multicenter Cohort Analysis.

Tamer G, van Santen H M, Bannier M A G E, Janssens H M, Manai B H A N, Swolfs R J M, van der Ent C K, Arets H G M, van der Kamp H J

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tamer GDepartment of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0002-9639-3894
van Santen H MDepartment of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.
Bannier M A G EDepartment of Pediatric Respiratory Medicine, MosaKids Children's Hospital, Maastricht University Medical Centre+, Maastricht, the Netherlands.ORCID https://orcid.org/0000-0003-4823-5872
Janssens H MDepartment of Pediatrics, division of Respiratory Medicine and Allergology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.
Manai B H A NDepartment of Pediatrics, division of Respiratory Medicine and Allergology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.
Swolfs R J MDepartment of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.
van der Ent C KDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.
Arets H G MDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.
van der Kamp H JDepartment of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesShort stature has been associated with reduced life expectancy in people with Cystic Fibrosis (pwCF). We aimed to evaluate linear growth and final height in a Dutch cohort of children with CF, diagnosed in early childhood and now aged ≥ 18 years and identify risk factors for impaired linear growth.

methodsA multicenter longitudinal retrospective cohort study was performed in pwCF born between 1997 and 2004, before implementation of newborn screening (NBS). Anthropometric measurements and CF-related risk factors for poor growth (pulmonary infections, malnutrition, CF-Related Diabetes [CFRD], CF-related liver disease [CFLD]) were obtained annually from ages 0.5 to 10 years and biannually from ages 10 to 18. Measurements were converted to Height-For-Age-For-Target-Height (HFA-TH) Z-scores. Differences in HFA-TH Z-scores between pwCF and healthy standards, and risk factors associated with linear growth were analyzed.

resultsA total of 128 pwCF (60 males) were included. Most patients did not receive modulator-therapy during pubertal growth. In boys, mean HFA-TH Z-scores at age 18 years (HFA-TH

conclusionBoys with CF may have impaired final height, especially those with CFRD or a ΔBMI

Indexed as

Body HeightCystic FibrosisGrowth DisordersAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornLongitudinal StudiesMaleNetherlandsRetrospective StudiesRisk FactorsBMIcystic fibrosis‐related diabetesfinal heightgrowthpulmonary function

Identifiers

PMID41711426
PMCPMC12918834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.